La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Shineco Bilan de santé

Santé financière contrôle des critères 3/6

Shineco possède un total de capitaux propres de $46.7M et une dette totale de $30.0M, ce qui porte son ratio d'endettement à 64.1%. Son actif total et son passif total sont $101.7M et de $55.0M.

Informations clés

64.1%

Ratio d'endettement

US$29.95m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$610.32k
Fonds propres	US$46.70m
Total du passif	US$54.98m
Total des actifs	US$101.69m

Mises à jour récentes de la santé financière

Recent updates

Shineco CEO steps down, new CEO appointed

May 07

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

May 04

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de SISI ( $22.4M ) ne couvrent pas ses passifs à court terme ( $43.4M ).

Passif à long terme: Les actifs à court terme de SISI ( $22.4M ) dépassent ses passifs à long terme ( $11.6M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de SISI ( 62.8% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de SISI est passé de 3.4% à 64.1% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: SISI dispose d'une piste de trésorerie suffisante pour 1 mois sur la base du dernier flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Prévisions de trésorerie: SISI devrait disposer d'une marge de trésorerie suffisante pour 1 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Shineco Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Requirement Under Nasdaq Listing Rule 5550(a)(2)

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Not Regains Compliance with the Nasdaq's Minimum Bid Price Requirement

Shineco Receives Deficiency Letter from Nasdaq

Shineco, Inc. announced delayed 10-Q filing

Recent updates

Shanchun Huang Engages in Discussions with Shineco

Shanchun Huang Engages in Discussions with Shineco

Shineco, Inc. has filed a Follow-on Equity Offering.

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Requirement Under Nasdaq Listing Rule 5550(a)(2)

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New major risk - Financial position

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

New major risk - Share price stability

New major risk - Financial position

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.60 loss in FY 2022)

Shineco Not Regains Compliance with the Nasdaq's Minimum Bid Price Requirement

Shineco, Inc.'S Subsidiary, Changzhou Biowin Pharmaceutical Co., Ltd., Receives Marketing Approval from China's Regulatory Body for Its Cardiac 5 Minute Test

New major risk - Market cap size

Shineco, Inc., Annual General Meeting, Jun 28, 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.30 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2022)

Shineco, Inc. (NasdaqCM:SISI) signed a letter of intent to acquire 80% stake in Dream Partner Limited for $40 million.

First quarter 2023 earnings released: US$0.17 loss per share (vs US$1.34 loss in 1Q 2022)

High number of new and inexperienced directors

Shineco Receives Deficiency Letter from Nasdaq

Full year 2022 earnings released: US$2.60 loss per share (vs US$4.73 loss in FY 2021)

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Shineco, Inc. Resigns Yanzeng as Member of the Board of Directors

High number of new and inexperienced directors

Shineco, Inc. Announces Management Changes

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shineco, Inc. Appoints Qiyin Sun as Chief Medical Consultant

High number of new directors

Shineco, Inc. (NasdaqCM:SISI) entered into an agreement to acquire 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd.

Independent Director Harry Edelson has left the company

High number of new directors

Third quarter 2021 earnings released: US$2.36 loss per share (vs US$1.26 loss in 3Q 2020)

Shineco CEO steps down, new CEO appointed

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding terms of proposal to acquire a 51% stake in Mayah Biological Holdings Limited.

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

Shineco, Inc. announced delayed 10-Q filing

New 90-day high: US$4.15

New 90-day high: US$3.82

New 90-day high: US$3.31

First quarter 2021 earnings released: US$0.35 loss per share

Full year earnings released - US$2.25 loss per share

New 90-day low - US$2.71

Shineco, Inc. Announces Management Changes

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding Letter of Intent to acquire 73.7% stake in Changzhou Biowin Pharmaceutical Co., Ltd from Beijing Kanghuayuan Technology Development Co., Ltd and Changzhou Kelinbo Venture Capital Partnership (limited partnership) for $25 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines